Trop2-targeted immunoPET ligands.

IF 2 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

American journal of nuclear medicine and molecular imaging Pub Date : 2025-06-25 eCollection Date: 2025-01-01 DOI:10.62347/GHKA7738

Steven H Liang

引用次数: 0

Abstract

Trop2 is overexpressed in various tumors and serves as a key biomarker. Targeted immunoPET ligands, mainly developed from Trop2 monoclonal antibodies and nanobodies, provide the landscape of heterogeneous expression of Trop2 in tumors, which has great potential in improving accuracy of cancer diagnosis and staging, as well as decision-making in therapy.

查看原文本刊更多论文

trop2靶向免疫pet配体。

Trop2在多种肿瘤中过表达，是关键的生物标志物。靶向免疫pet配体主要由Trop2单克隆抗体和纳米体发展而来，提供了Trop2在肿瘤中异质表达的前景，在提高癌症诊断和分期的准确性以及治疗决策方面具有很大的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of nuclear medicine and molecular imaging RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

自引率

4.00%

发文量

期刊介绍： The scope of AJNMMI encompasses all areas of molecular imaging, including but not limited to: positron emission tomography (PET), single-photon emission computed tomography (SPECT), molecular magnetic resonance imaging, magnetic resonance spectroscopy, optical bioluminescence, optical fluorescence, targeted ultrasound, photoacoustic imaging, etc. AJNMMI welcomes original and review articles on both clinical investigation and preclinical research. Occasionally, special topic issues, short communications, editorials, and invited perspectives will also be published. Manuscripts, including figures and tables, must be original and not under consideration by another journal.